L J Patterson

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint The "STEP-wise" future of adenovirus-based HIV vaccines
    L J Patterson
    Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Med Chem 18:3981-6. 2011
  2. pmc Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus
    M Robert-Guroff
    Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4255, USA
    J Virol 72:10275-80. 1998
  3. ncbi request reprint A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge
    L J Patterson
    Basic Research Laboratory, National Cancer Institute, Bethesda, Maryland 20892, USA
    AIDS Res Hum Retroviruses 17:837-49. 2001
  4. ncbi request reprint Formation of HIV-1 envelope-hepatitis B core antigen hybrids with high affinity for CD4
    L J Patterson
    Laboratory of Immunoregulation, Office of Vaccine Research and Review, FDA National Institutes of Health, NIH Campus Bldg 29, Bethesda, MD 20892, USA
    Biochem Biophys Res Commun 285:639-43. 2001

Collaborators

  • S Zolla-Pazner
  • M Robert-Guroff
  • F Sinangil
  • H Kaur
  • L Murty
  • P D Markham
  • A J Conley
  • P M McKenna
  • E Richardson
  • K Aldrich
  • M Leno
  • L Carter
  • K Arora

Detail Information

Publications4

  1. ncbi request reprint The "STEP-wise" future of adenovirus-based HIV vaccines
    L J Patterson
    Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Med Chem 18:3981-6. 2011
    ..Finally, evaluation of replicating adenovirus vectors known to be capable of inducing potent cellular, humoral, and mucosal immunity will be vital to meeting our future goal of an effective HIV vaccine...
  2. pmc Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus
    M Robert-Guroff
    Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4255, USA
    J Virol 72:10275-80. 1998
    ..These results demonstrate the potential of this combination vaccine strategy and suggest that vaccine protection against an HIV isolate relevant to infection of people is feasible...
  3. ncbi request reprint A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge
    L J Patterson
    Basic Research Laboratory, National Cancer Institute, Bethesda, Maryland 20892, USA
    AIDS Res Hum Retroviruses 17:837-49. 2001
    ..In spite of the peptomer's strong immunogenicity and potential for induction of broadly protective immune responses, it was not effective as a subunit vaccine...
  4. ncbi request reprint Formation of HIV-1 envelope-hepatitis B core antigen hybrids with high affinity for CD4
    L J Patterson
    Laboratory of Immunoregulation, Office of Vaccine Research and Review, FDA National Institutes of Health, NIH Campus Bldg 29, Bethesda, MD 20892, USA
    Biochem Biophys Res Commun 285:639-43. 2001
    ..By combining the immunogenicity of the carrier protein with the antigenicity of gp120, these hybrids may lead to modified HIV-1 antigens with enhanced immunogenicity...